1
|
Reachi B, Negrelli J, Rapier M, Hickman A. 4-Factor Prothrombin Complex Concentrate Dosing Strategies: A Retrospective Evaluation. J Pharm Pract 2024; 37:287-295. [PMID: 36206169 DOI: 10.1177/08971900221131924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
ObjectivesDetermine indication specific 4-Factor prothrombin complex concentrate (4FPCC) dosing strategies within a hospital system and subsequent effectiveness. Background: 4FPCC is FDA approved for reversal of vitamin K antagonists (VKA) for acute major bleeding or need for urgent surgery/invasive procedure. Since its approval, off label use has expanded to include direct oral anticoagulant reversal and perioperative hemostasis. Optimal dosing strategies remain controversial, and recent studies have evaluated fixed-dose regimens with lower doses than those recommended in product labeling. Methods/Materials: Retrospective cohort with manual chart review for patients who received 4FPCC spanning 2 years. Primary outcome was to characterize dosing. Secondary outcomes were INR normalization, hemostatic efficacy, in-hospital mortality, and renal function change. Results: Of the 300 patients evaluated, 80% received 4FPCC for anticoagulant reversal, with 66% of those for VKA and 34% for DOAC. The remaining 20% received 4FPCC for a non-reversal indication. Of the patients requiring anticoagulation reversal, 25% received doses lower than recommended and 6% received higher. 71% of patients received 4FPCC for life-threatening bleed, and 45% of them had intracranial hemorrhage. Higher mortality with higher than recommended doses was the only statistically significant secondary outcome (P = .018). Conclusion: We found that lower doses than recommended were used in a significant number of patients. The higher than recommended doses group constituted a small proportion of patients and the higher mortality was attributed to patient acuity on presentation. Additional studies evaluating dosing approach are required to determine lowest effective dosing for various indications.
Collapse
Affiliation(s)
- Breyanna Reachi
- Department of Pharmacy, Intermountain Medical Center, Murray, UT, USA
| | - Jenna Negrelli
- Department of Pharmacy, Loyola University Medical Center, Maywood, IL, USA
| | - Marie Rapier
- Department of Pharmacy, Intermountain Medical Center, Murray, UT, USA
| | - Abby Hickman
- Department of Pharmacy, Intermountain Medical Center, Murray, UT, USA
| |
Collapse
|
2
|
Tritle BJ, Watteyne R, Hickman A, Vento TJ, Lopansri BK, Collingridge DS, Veillette JJ. No Implementation Without Representation: Real-Time Pharmacist Intervention Optimizes Rapid Diagnostic Tests for Bacteremia at a Small Community Hospital. Hosp Pharm 2021; 57:377-384. [DOI: 10.1177/00185787211037554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background: Rapid diagnostic tests (RDTs) for bacteremia allow for early antimicrobial therapy modification based on organism and resistance gene identification. Studies suggest patient outcomes are optimized when infectious disease (ID)-trained antimicrobial stewardship personnel intervene on RDT results. However, data are limited regarding RDT implementation at small community hospitals, which often lack access to on-site ID clinicians. Methods: This study evaluated the impact of RDTs with and without real-time pharmacist intervention (RTPI) at a small community hospital with local pharmacist training and asynchronous support from a remote ID Telehealth pharmacist. Time to targeted therapy (TTT) in patients with bacteremia was compared retrospectively across 3 different time periods: a control without RDT, RDT-only, and RDT with RTPI. Results: Median TTT was significantly faster in both the RDT with RTPI and RDT-only groups compared with the control group (2 vs 25 vs 51 hours respectively; P < .001). TTT was numerically faster for RDT with RTPI compared with RDT-only but did not reach statistical significance ( P = .078). Median time to any de-escalation was significantly shorter for RDT with RTPI compared with both RDT-only (14 vs 33 hours; P = .012) and the control group (14 vs 45 hours; P < .001). Median length of stay was also significantly shorter in both RDT groups compared with the control group (4.0 vs 4.1 vs 5.5 hours; P = .013). Conclusion: This study supports RDT use for bacteremia in a small community hospital with ID Telehealth support, suggesting additional benefit with RTPI.
Collapse
Affiliation(s)
- Brandon J. Tritle
- Department of Pharmacy, Intermountain Healthcare, Intermountain Medical Center, Murray, UT, USA
| | - Robert Watteyne
- Department of Pharmacy, Intermountain Healthcare, Logan Regional Hospital, Logan, UT, USA
| | - Abby Hickman
- Department of Pharmacy, Intermountain Healthcare, Intermountain Medical Center, Murray, UT, USA
| | - Todd J. Vento
- Infectious Diseases Telehealth Service, Intermountain Healthcare, Intermountain Medical Center, Murray, UT, USA
- Division of Infectious Diseases and Epidemiology, Intermountain Healthcare, Intermountain Medical Center, Murray, UT, USA
| | - Bert K. Lopansri
- Division of Infectious Diseases and Epidemiology, Intermountain Healthcare, Intermountain Medical Center, Murray, UT, USA
| | - Dave S. Collingridge
- Office of Research, Intermountain Healthcare, Intermountain Medical Center, Murray, UT, USA
| | - John J. Veillette
- Department of Pharmacy, Intermountain Healthcare, Intermountain Medical Center, Murray, UT, USA
- Infectious Diseases Telehealth Service, Intermountain Healthcare, Intermountain Medical Center, Murray, UT, USA
| |
Collapse
|
3
|
Berenbaum F, Schnitzer T, Kivitz A, Viktrup L, Hickman A, Pixton G, Brown M, Davignon I, West C. FRI0378 GENERAL SAFETY AND TOLERABILITY OF SUBCUTANEOUS TANEZUMAB FOR THE TREATMENT OF OSTEOARTHRITIS: A POOLED ANALYSIS OF RANDOMIZED, PLACEBO-CONTROLLED TRIALS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the treatment of signs and symptoms of osteoarthritis (OA).Objectives:To assess the safety and tolerability of subcutaneous (SC) tanezumab in patients with OA.Methods:Data were derived from 3 randomized placebo-controlled OA trials. SC treatment (every 8 weeks for 16–24 weeks with 8–24 week follow-up) included placebo, tanezumab 2.5 mg, tanezumab 2.5/5 mg (2.5 mg at day 1 and 5 mg at week 8), and tanezumab 5 mg. Overall treatment-emergent adverse events (TEAEs) and TEAEs of abnormal peripheral sensation were pooled from all 3 trials (placebo N = 586; tanezumab: 2.5 mg N = 602, 2.5/5 mg N = 219, 5 mg N = 347). Pre-specified TEAEs potentially associated with sympathetic neuropathy (anhidrosis, bradycardia, hypohidrosis, orthostatic hypotension, or syncope) and pre-specified joint events (primary osteonecrosis, rapidly progressive OA [RPOA] type 1 or type 2, subchondral insufficiency fracture, or pathological fracture; adjudicated by an independent committee of experts) were pooled from the 2 trials that included prospective evaluation of sympathetic and joint safety (placebo N = 514; tanezumab: 2.5 mg N = 528, 2.5/5 mg N = 219, 5 mg N = 284). TEAEs are presented for the treatment period; joint safety is presented for the full study (treatment plus follow up) period.Results:Patient demographics (80.7% white, 66.8% female, mean age ≈ 63 years) and clinical characteristics were similar across groups. TEAE rates were: placebo = 51.7%, tanezumab 2.5 mg = 52.3%, tanezumab 2.5/5 mg = 47.0%, and tanezumab 5 mg = 54.8%. Of TEAEs occurring in ≥2% of patients in any group, only oedema peripheral, joint stiffness, and paraesthesia had a higher incidence (95% confidence interval excluded 0) in any tanezumab group relative to placebo. Serious TEAE rates were: placebo = 1.5%, tanezumab 2.5 mg = 2.2%, tanezumab 2.5/5 mg = 1.4%, and tanezumab 5 mg = 2.6%. Rates of treatment and/or study discontinuation due to TEAEs were: placebo = 2.2%, tanezumab 2.5 mg = 1.8%, tanezumab 2.5/5 mg = 0.5%, and tanezumab 5 mg = 1.4%. Only arthralgia and OA led to discontinuation in >1 patient in any group. TEAEs of abnormal peripheral sensation rates were: placebo = 2.2%, tanezumab 2.5 mg = 5.1%, tanezumab 2.5/5 mg = 3.2%, and tanezumab 5 mg = 6.1%. Paraesthesia and hypoaesthesia were the most common events. Potential sympathetic neuropathy TEAE rates were: placebo = 0.8%, tanezumab 2.5 mg = 1.5%, tanezumab 2.5/5 mg = 0.5%, and tanezumab 5 mg = 2.8%; exposure-adjusted rates were not statistically different between any tanezumab group and placebo. Bradycardia and orthostatic hypotension were the most common events. No patient was considered to have a sympathetic neuropathy. TEAEs of abnormal peripheral sensation and potential sympathetic neuropathy were mostly mild and resolved. Joint safety event rates were statistically different for tanezumab 5mg (3.2%), but not 2.5mg (1.9%) or 2.5/5mg (0.5%), compared to placebo (0%). RPOA type-1 was the most common event. Total joint replacement rates were: placebo = 4.5%, tanezumab 2.5 mg = 5.9%, tanezumab 2.5/5 mg = 6.8%, and tanezumab 5 mg = 7.0%; rates were not statistically different between any tanezumab group and placebo.Conclusion:Tanezumab was generally safe and well tolerated in most patients, with rates of overall TEAEs and treatment/study discontinuations similar to placebo and no evidence of a sympathetic safety signal. TEAEs of abnormal peripheral sensation and joint safety events were infrequent but more common with tanezumab than placebo.Disclosure of Interests:Francis Berenbaum Grant/research support from: TRB Chemedica (through institution), MSD (through institution), Pfizer (through institution), Consultant of: Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Bone Therapeutics, Regulaxis, Peptinov, 4P Pharma, Paid instructor for: Sandoz, Speakers bureau: Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Sandoz, Thomas Schnitzer Consultant of: Pfizer, Lilly, AstraZeneca, GSK, Alan Kivitz Shareholder of: AbbVie, Amgen, Gilead, GSK, Pfizer Inc, Sanofi, Consultant of: AbbVie, Boehringer Ingelheim,,Flexion, Genzyme, Gilead, Janssen, Novartis, Pfizer Inc, Regeneron, Sanofi, SUN Pharma Advanced Research, UCB, Paid instructor for: Celgene, Genzyme, Horizon, Merck, Novartis, Pfizer, Regeneron, Sanofi, Speakers bureau: AbbVie, Celgene, Flexion, Genzyme, Horizon, Merck, Novartis, Pfizer Inc, Regeneron, Sanofi, Lars Viktrup Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Anne Hickman Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Glenn Pixton Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Mark Brown Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Isabelle Davignon Shareholder of: Pfizer, Employee of: Pfizer, Christine West Shareholder of: Pfizer Inc, Employee of: Pfizer Inc
Collapse
|
4
|
Berenbaum F, Kivitz A, Schnitzer T, Brown M, Donevan S, Hickman A, Viktrup L, West C, Yamabe T. FRI0392 ADVERSE EVENTS IN PATIENTS WITH OSTEOARTHRITIS TREATED WITH SUBCUTANEOUS TANEZUMAB: A POOLED ANALYSIS OF THE OVERALL POPULATION AND SELECTED SUBGROUPS FROM 3 RANDOMISED PLACEBO-CONTROLLED TRIALS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.3701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Tanezumab, a monoclonal antibody against nerve growth factor (NGF), is in development for the treatment of osteoarthritis (OA).Objectives:To assess the effects of gender, age and body mass index (BMI) on the incidence of adverse events (AEs) in patients (pts) treated with subcutaneous (SC) tanezumab in pooled data from three phase 3 OA studies. Anti-NGF therapy has been associated with joint safety events1. Here we focus on treatment emergent AEs, including abnormalities of peripheral sensation (APS).Methods:All three randomised, double-blind, placebo-controlled studies enrolled pts with radiographically-confirmed OA of the hip or knee, who had inadequate response or could not tolerate standard of care analgesics. In the 16-week (wk) Study 1 (NCT01089725), pts received placebo, tanezumab 2.5 mg, 5 mg or 10 mg at baseline and wk 82. Due to a clinical hold on NGF antibodies, <10% of pts received the 2nddose at wk 8. Pts in the 16-wk Study 2 (NCT02697773), received placebo or tanezumab 2.5 mg at baseline and wk 8 or tanezumab 2.5mg at baseline and 5mg at wk 81. Pts in the 24-wk Study 3 (NCT02709486), received placebo, tanezumab 2.5 mg or 5 mg at baseline, wks 8 and 16. All treatments were given SC. AE data from the treatment period of each study were pooled for placebo, tanezumab 2.5 mg and 5 mg groups and examined by subgroups of gender, age and BMI. Data from the 10 mg group of Study 1 were not included due to the low sample size.Results:The incidence of any AE was numerically higher in females across treatment groups and in pts with a BMI ≥30 kg/m2in the tanezumab 5mg, but not 2.5 mg group, vs the overall population (Table 1). SAEs were infrequent but numerically higher across all tanezumab 5 mg subgroups vs placebo (Table 2). Paraesthesia and hypoaesthesia were the most common AEs of APS and were increased in all tanezumab groups in the overall population vs placebo. In any of the subgroups, the incidence of paraesthesia or hypoaesthesia was ≤7.8% and ≤3.9%, respectively. The difference within a patient subgroup for paraesthesia or hypoaesthesia was typically comparable with that of the overall population across treatments.Table 1.Incidence of AEs during the treatment period% of pts with an AE in each subgroupPlacebon=586Tanezumab2.5 mgn=602Tanezumab2.5 mg/5 mg n=219Tanezumab5 mgn=347Overall population51.752.347.054.8Gender Male51.149.741.346.6 Female52.053.650.459.0Age (years) <6555.054.044.054.5 ≥6547.250.052.654.9BMI (kg/m2) <2558.146.651.945.5 25–<3051.455.943.750.0 30–<3549.251.543.258.9 ≥3552.752.355.360.9BMI, body mass index; kg/m2, kilogram per square metreTable 2.Incidence of SAEs during the treatment period% of pts with a SAE in each subgroupPlacebon=586Tanezumab2.5 mgn=602Tanezumab2.5 mg/5 mg n=219Tanezumab5 mgn=347Overall population1.52.21.42.6Gender Male1.63.01.32.5 Female1.51.71.42.6Age (years) <651.22.61.41.9 ≥652.01.61.33.1BMI (kg/m2) <251.61.102.3 25–<301.62.702.7 30–<351.62.01.43.1 ≥351.32.34.31.6BMI, body mass index; kg/m2, kilogram per square metreConclusion:This pooled analysis showed that the safety profile of tanezumab in the subgroups studied is broadly similar to that of the overall study population.References:[1]Schnitzer, T. J.et al. JAMA(2019)[2]Birbara, C.et al. J Pain Res(2018)Disclosure of Interests:Francis Berenbaum Grant/research support from: TRB Chemedica (through institution), MSD (through institution), Pfizer (through institution), Consultant of: Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Bone Therapeutics, Regulaxis, Peptinov, 4P Pharma, Paid instructor for: Sandoz, Speakers bureau: Novartis, MSD, Pfizer, Lilly, UCB, Abbvie, Roche, Servier, Sanofi-Aventis, Flexion Therapeutics, Expanscience, GSK, Biogen, Nordic, Sandoz, Regeneron, Gilead, Sandoz, Alan Kivitz Shareholder of: AbbVie, Amgen, Gilead, GSK, Pfizer Inc, Sanofi, Consultant of: AbbVie, Boehringer Ingelheim,,Flexion, Genzyme, Gilead, Janssen, Novartis, Pfizer Inc, Regeneron, Sanofi, SUN Pharma Advanced Research, UCB, Paid instructor for: Celgene, Genzyme, Horizon, Merck, Novartis, Pfizer, Regeneron, Sanofi, Speakers bureau: AbbVie, Celgene, Flexion, Genzyme, Horizon, Merck, Novartis, Pfizer Inc, Regeneron, Sanofi, Thomas Schnitzer Consultant of: Pfizer, Lilly, AstraZeneca, GSK, Mark Brown Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Sean Donevan Shareholder of: Pfizer Inc., Employee of: Pfizer Inc., Anne Hickman Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Lars Viktrup Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Christine West Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Takaharu Yamabe Shareholder of: Pfizer, Employee of: Pfizer
Collapse
|
5
|
Reachi B, Negrelli J, Hickman A, Beesley S, Osborn J. 213: ISOPROTERENOL AND LIDOCAINE FOR RECURRENT TORSADES DE POINTES IN A 32-YEAR-OLD PREGNANT WOMAN. Crit Care Med 2020. [DOI: 10.1097/01.ccm.0000619208.43771.ff] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Sahasrabudhe V, Terra SG, Hickman A, Saur D, Shi H, O'Gorman M, Zhou Z, Cutler DL. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus. J Clin Pharmacol 2017; 57:1432-1443. [PMID: 28703316 PMCID: PMC5655776 DOI: 10.1002/jcph.955] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Revised: 04/28/2017] [Accepted: 05/09/2017] [Indexed: 01/02/2023]
Abstract
Ertugliflozin is a highly selective and potent inhibitor of the sodium-glucose cotransporter 2 in development for the treatment of type 2 diabetes mellitus. The glycemic efficacy of sodium-glucose cotransporter 2 inhibitors such as ertugliflozin depends on glucose filtration through the kidney. This phase 1, open-label study evaluated the effect of renal impairment on the pharmacokinetics, pharmacodynamics, and tolerability of ertugliflozin (15 mg) in type 2 diabetes mellitus and healthy subjects with normal renal function (estimated glomerular filtration rate not normalized for body surface area ≥90 mL/min) and type 2 diabetes mellitus subjects with mild (60-89 mL/min), moderate (30-59 mL/min), or severe (<30 mL/min) renal impairment (n = 36). Blood and urine samples were collected predose and over 96 hours postdose for pharmacokinetic evaluation and measurement of urinary glucose excretion over 24 hours. Log-linear regression analyses indicated predicted mean area under the concentration-time curve values for mild, moderate, and severe renal function groups that were ≤70% higher relative to subjects with normal renal function. Generally consistent results were obtained with categorical analysis based on analysis of variance. The increase in ertugliflozin exposure in subjects with renal impairment is not expected to be clinically meaningful. Regression analysis of change from baseline in urinary glucose excretion over 24 hours vs estimated glomerular filtration rate showed a decrease in urinary glucose excretion with declining renal function. A single 15-mg dose of ertugliflozin was well tolerated in all groups.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Z Zhou
- Merck & Co., Inc., Kenilworth, NJ, USA
| | | |
Collapse
|
7
|
Hickman A, Stowman A, Gru A, Slingluff C. 348 Histopathologic review of negative sentinel lymph node biopsies in thin melanomas: An argument for the routine use of immunohistochemistry and serial sectioning. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Caley A, Hickman A, Frantzeskou K, Hudson E, Parker K, Appadurai I, Rayment R, Noble S, Hanna L. PO-257 DEEP VENOUS THROMBOSIS (DVT) RATES IN PATIENTS RECEIVING BRACHYTHERAPY FOR CERVICAL CANCER. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)72223-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Klein DC, Ganguly S, Coon SL, Shi Q, Gaildrat P, Morin F, Weller JL, Obsil T, Hickman A, Dyda F. 14-3-3 proteins in pineal photoneuroendocrine transduction: how many roles? J Neuroendocrinol 2003; 15:370-7. [PMID: 12622836 DOI: 10.1046/j.1365-2826.2003.01000.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Recent studies suggest that a common theme links the diverse elements of pineal photoneuroendocrine transduction--regulation via binding to 14-3-3 proteins. The elements include photoreception, neurotransmission, signal transduction and the synthesis of melatonin from tryptophan. We review general aspects of 14-3-3 proteins and their biological function as binding partners, and also focus on their roles in pineal photoneuroendocrine transduction.
Collapse
Affiliation(s)
- D C Klein
- Section on Neuroendocrinology, Laboratory of Developmental Neurobiology, National Institute of Child Health and Human Development/NIH 49/6A82, Bethesda, MD 20892-4480, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Klein DC, Ganguly S, Coon S, Weller JL, Obsil T, Hickman A, Dyda F. 14-3-3 Proteins and photoneuroendocrine transduction: role in controlling the daily rhythm in melatonin. Biochem Soc Trans 2002; 30:365-73. [PMID: 12196096 DOI: 10.1042/bst0300365] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
This paper describes the role 14-3-3 proteins play in vertebrate photoneuroendocrine transduction. 14-3-3 proteins form a complex with arylalkylamine N-acetyltransferase (AANAT), the enzyme which turns melatonin production on during the day and off at night. Complex formation is triggered at night by cAMP-dependent phosphorylation of the enzyme, and results in activation and protection against proteolysis. This enhances melatonin production >10-fold. Light exposure results in dephosphorylation of the enzyme and disassociation from 14-3-3, leading to destruction and a rapid drop in melatonin production and release and circulating levels.
Collapse
Affiliation(s)
- D C Klein
- Section on Neuroendocrinology, Laboratory of Developmental Neurobiology, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-4480, USA.
| | | | | | | | | | | | | |
Collapse
|
11
|
Choudhury K, Sundaramoorthy M, Hickman A, Yonetani T, Woehl E, Dunn MF, Poulos TL. Role of the proximal ligand in peroxidase catalysis. Crystallographic, kinetic, and spectral studies of cytochrome c peroxidase proximal ligand mutants. J Biol Chem 1994; 269:20239-49. [PMID: 8051115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
The role of the proximal histidine ligand in peroxidase function was studied by replacing the His side chain in cytochrome c peroxidase with Gln, Glu, or Cys. In addition, a double mutant was prepared where His-175 is converted to Gln and the site of free radical formation in Compound I, Trp-191 (Sivaraja, M., Goodin, D.B., Smith, M., and Hoffman, B. M. (1989) Science 245, 738-740), is converted to Phe. With the exception of the His-175-->Cys mutant, the proximal ligand mutants retain high levels of enzyme activity. Stopped flow studies show that replacing the His ligand with Gln has only a modest effect on the rate of Compound I formation demonstrating that the precise nature of the proximal ligand is not important in achieving a high rate of peroxide O-O bond cleavage. The double mutant, His-175-->Gln/Trp-191-->Phe, also forms Compound I rapidly but the initial product formed is very likely a long-lived porphyrin pi cation radical that slowly converts to a species more closely resembling the heme oxyferryl center of wild type Compound I. The relevance of these studies to the cytochrome c peroxidase-cytochrome c electron transfer system are discussed.
Collapse
Affiliation(s)
- K Choudhury
- Department of Molecular Biology & Biochemistry, University of California, Irvine 92717-3900
| | | | | | | | | | | | | |
Collapse
|
12
|
Choudhury K, Sundaramoorthy M, Hickman A, Yonetani T, Woehl E, Dunn M, Poulos T. Role of the proximal ligand in peroxidase catalysis. Crystallographic, kinetic, and spectral studies of cytochrome c peroxidase proximal ligand mutants. J Biol Chem 1994. [DOI: 10.1016/s0021-9258(17)31982-8] [Citation(s) in RCA: 90] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
13
|
Hickman A, Wilson SK, Stein M, Lewis J. Portal and superior mesenteric venous thrombosis following splenectomy. J Tenn Med Assoc 1991; 84:329-30. [PMID: 1870345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- A Hickman
- Department of Surgery, James H. Quillen College of Medicine, East Tennessee State University, Johnson City
| | | | | | | |
Collapse
|
14
|
Wink D, Anderson A, Byon C, Collet T, Hickman A, Miller AF, Salifoglou T, Sharpless K, Orme-Johnson W. Homocitrate complexes: Role in MoFe cofactor synthesis and function in nitrogenase. J Inorg Biochem 1989. [DOI: 10.1016/0162-0134(89)84080-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
15
|
McLean P, Wink D, Coucouvanis D, Hickman A, Salifoglou T, Wright D, Orme-Johnson W. MoFe Cofactor of nitrogenase: Extraction, purification, and characterization. J Inorg Biochem 1989. [DOI: 10.1016/0162-0134(89)84088-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
16
|
Abstract
A study to determine the value of the BACTEC resin-containing medium, 16B, used in conjunction with radiometric detection of bacteremia using three media was conducted. During a six-month period, 2,104 blood-culture sets consisting of the four media (6B, 7C, 8B, and 16B) were collected. There were 158 significant positive cultures (excluding contaminants) that yielded 168 pathogenic isolates. The data were divided into two patient groups: patients receiving antibiotics and patients not receiving antibiotics. In contrast to previous studies, there was no significant difference in the detection rate of significant positive cultures by the different media in either group of patients. However, in patients receiving antimicrobial therapy, 41 of 55 significant positive cultures (74.5%) were detected by 16B medium, while 34 of 55 (61.8%) were detected by 6B medium. Although this difference is not statistically significant, this trend suggests that 16B medium may be useful in these patients. However, the isolation rate of significant positive cultures is the same for the resin medium and the hypertonic aerobic medium for both groups of patients. Thus, it is possible that the hypertonic medium is as efficacious as resin-containing media in blood culturing.
Collapse
|
17
|
|
18
|
Hickman A. Treatment of Cholera with Sulphurous Acid. Ind Med Gaz 1882; 17:321. [PMID: 28998879 PMCID: PMC5151926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|